Precision medicine is a growing approach for the treatment of disease and preventive health. According to MRFR reports, the precision medicine market size will likely hit USD 126.14 billion by the end of 2030, with a CAGR of 12.48%. The precision medicine market allows the patient's participation in taking care of personal health and offers more targeted therapies to the individuals that will propel the Precision Medicine Market growth in the coming years. The growing prevalence of numerous genetic diseases is anticipated to boost the growth of the precision medicine market. The introduction of pharma and biotech industries with big data healthcare companies is likely to propel precision medicine market growth.
The growth of the Precision Medicine Market is attributed to many growth drivers like the rise of data-driven healthcare, increasing incidence rate of cancer, cost-effective profiling of DNA, companion diagnostic assay, and increasing approval of the drug. Furthermore, the rising use of 'multi-omics' in research and the penetration of high-throughput sequencing platforms is also likely to fuel the market's growth in a forecasted period. The present rise in the price of drug discovery with the rise in regulatory needs has boosted the demand for personalized medicines, which is offering momentum to market growth. However, the increased costs of diagnosis and rise in concerns regarding data security might impede the market's growth.
Precision Medicine Market Overview, Growth, Trends and Size Analysis by Ecosystem Players (Pharmaceuticals and Biotechnology Companies, Diagnostic Companies, Healthcare IT Specialists/Big Data Companies and Clinical Laboratories), Sub-Markets (Companion Diagnostics, Biomarker-Based Test, Targeted Therapeutics, Pharmacogenomics (PGX), Molecular Diagnostics and others), Therapeutics (Cancer/Oncology, Cardiovascular Disease (CVD), Central Nervous System, Infectious Diseases and others) and Region (Americas, Europe, Asia-Pacific and Middle East Africa)
Competitive Analysis
The list of prominent Precision Medicine Market Players growth includes the companies like
- CETICS Healthcare Technologies GmbH,
- Cepheid Inc.,
- bioMérieux SA,
- Almac Group, Ltd.,
- GlaxoSmithKline Plc (GSK),
- Johnson Johnson,
- Pfizer Inc, Qiagen,
- Randox Laboratories Ltd,
- Quest Diagnostics Inc.,
- Roche Holding AG-Br,
- Caris Life Sciences,
- HealthCore, Inc.,
- Molecular Health GmbH, and
- Precision for Medicine,
- IBM,
- Intel Corporation,
- Sanofi Pharma,
- BIOBASE GmbH (Subsidiary),
- Intomics A/S,
- ASURAGEN, Inc.,
- ABBOTT LABORATORIES,
- LABORATORY CORPORATION OF AMERICA HOLDINGS and many others.
Segment Analysis
The global Precision Medicine Market Research is bifurcated into numerous segments based on ecosystem players, therapeutics, and submarkets.
- Based on sub-markets, the classification is done as molecular diagnostics, targeted therapeutics, pharmacogenomics or PGX, companion diagnostics, biomarker-based tests, and many more.
- The global precision medicine market segmentation based on therapeutics includes infectious disease, cancer or oncology, central nervous system, cardiovascular disease or CVD, and others. The ecosystem players segment includes healthcare IT specialists or big data companies, clinical laboratories, pharmaceuticals, biotechnology companies, and diagnostics companies.
Regional Analysis
On the basis of geography, the Precision Medicine Market Report is divided into regions like the Middle East, Africa, Europe, Asia-Pacific, Latin America, and North America. Among all these, the North American regional market for precision medicines is projected to account for the largest market share in the forecasted period. The growth of advanced gene mapping technologies is the major factor boosting the regional market growth. The European region has been recorded as the second-largest shareholder in the global precision medicine market attributed to better electronic health care records, drugs, and diagnostics tools. For the Asia Pacific region, the Singapore precision medicine market is likely to register substantial growth mainly due to the better healthcare infrastructure and increased disposable income.
Industry News
- Selvita has confirmed that its strategic investment has been concluded by acquiring Fidelta. The transaction completes soon after the very first notice. For a market valuation of €31.2 million plus standard allowance for total capital and corporate capital, Selvita bought 100 per cent of the shareholders' equity of Fidelta
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
